Novotech Health Holdings is a leading Asia-Pacific biotech specialist CRO and consists of two operating brands, "Novotech" and "PPC". Novotech is a clinical CRO with labs, phase I facilities, and drug development consulting services. It has accumulated experience in over 3,700 clinical projects, including Phase I to Phase IV clinical trials and bioequivalence studies. Novotech is positioned to serve biopharmaceutical clients conducting clinical trials in Asia and globally. As of March 31, 2021, Novotech had a total of 1,765 FTEs working across our offices in 11 geographies in Asia-Pacific and the United States.
Daniela holds a PhD in Chemistry from The University of Adelaide, South Australia, and has a strong research background having worked in the area of cardiovascular and heart-disease related drug development research for over 8 years. Daniela has over 15 years of experience in the clinical trial industry joining Pfizer Pharmaceuticals in 2006 before moving to Novotech in 2009. Since joining Novotech, Daniela has filled a number of positions within Clinical Operations, the most recent being appointed Director of Clinical Operations ANZ in 2018. In this role, Daniela leads a large team and is responsible for successful project delivery and quality of Clinical Operations services across the ANZ and Greater India region.
Kirsten has been with Novotech since early 2016 when she joined as an SCRA, bringing a wealth of experience in the clinical research industry from various positions in both pharmaceutical and CRO environments. Kirsten consistently challenges herself and progressed to Project Manager having proven her ability to perform her role to the highest standards. Kirsten has successfully managed studies across all phases of clinical research, including early phase healthy volunteer and infectious disease, dermatology, and oncology trials to late phase rare disease studies. Kirsten received exceptional praise from her study sponsors for her project management expertise and ability to consistently deliver above and beyond expectations. As a result, Kirsten was promoted to her current role in Business Development where she plays an integral role in supporting new clients in the development of robust clinical strategies for planned clinical trials. Kirsten is known for her calm and considered approach, exceptional leadership, and willingness to mentor junior team members. Kirsten’s strong scientific background, solid clinical research experience, and leadership skills, coupled with her enthusiasm and commitment to her responsibilities make her well regarded by her study teams.
Matty Culbreth-Notaro is the Chief Operating Officer at ObvioHealth. She has nearly 30 years of experience in clinical research, first as a critical care nurse and later, in leadership roles developing and implementing clinical research programs for multi-therapeutic area practices and hospitals across the country. She has managed advanced research programs specializing in phases I-IV, device, post-approval, observational, and now with ObvioHealth, decentralized clinical trials. Academically, Matty received a Bachelor of Science in Nursing from Florida State University.
Arsalan Arif is a news media entrepreneur who set out in 2015 to build his vision of an independent biotech news company at Endpoints News.